Interpace Biosciences, Inc. (IDXG) stock
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences, Inc. saw revenue fall 20.5% to $36.14M over the twelve months to Jun 30, 2026. Operating income fell 27.2% to $4.17M, moving the operating margin from 12.6% to 11.5%. Free cash flow was $4.10M. At the latest close the market valued the company at $138.57M, 5.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $138.57M
- P/E ratio
- 5.6
- Price to sales
- 3.83
- Price to book
- 5.96
- Dividend yield
- –
- Free cash flow yield
- 2.96%
Fundamentals
- Revenue
- $36.14M
- Net income
- $24.45M
- EPS, diluted
- $0.89
- Free cash flow
- $4.10M
- Book value per share
- $0.84
- Diluted shares
- 28M
Trading
- Next earnings
- Jan 19, 2027 (estimated, before the open)
- Previous close
- $5.15
- Open
- $5.09
- Day's range
- $5.00 – $5.82
- Volume
- 7,328
- Average volume (20 days)
- 2,375
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | IDXG | S&P 500 | Difference | IDXG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.5% | +0.6% | −23.1 pts | ||
| 3 months | +227.9% | +3.4% | +224.5 pts | ||
| Year to date | +306.4% | +13.3% | +293.2 pts | ||
| 1 year | +437.6% | +16.6% | +421.0 pts |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Interpace Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Interpace Biosciences
Surgical & Medical Instruments & Apparatus
Interpace Biosciences, Inc. is a commercial-stage company that provides molecular diagnostic testing and pathology services. The company specializes in evaluating cancer risk for patients with indeterminate biopsies and clinical indications of malignancy. Its commercialized offerings center on tests for thyroid cancer, specifically the ThyGeNEXT oncogenic mutation panel and the ThyraMIR v2 microRNA classifier, which are used in combination to inform surgical and treatment choices. Customers include physicians, hospitals, cancer centers, commercial laboratories, clinics, and pathology groups.
Company profile, executives and historyInterpace Biosciences stock: common questions
What is Interpace Biosciences's stock price?
IDXG closed at $5.00 on Oct 19, 2026, down 2.91% on the day.
What is Interpace Biosciences's market cap?
Interpace Biosciences was worth $138.57M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is IDXG's P/E ratio?
IDXG trades at 5.6 times earnings, based on diluted earnings per share of $0.89 over the twelve months to Jun 30, 2026.
How much revenue does Interpace Biosciences make?
Interpace Biosciences reported revenue of $36.14M for the twelve months to Jun 30, 2026, down 20.5% from a year earlier.
Does Interpace Biosciences pay a dividend?
No. Interpace Biosciences has not paid a cash dividend over the last twelve months.
When does Interpace Biosciences report earnings next?
Interpace Biosciences is expected to report Q4 FY2026 results on Jan 19, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IDXG stock performed over the past year?
Including dividends, IDXG returned +437.6% over the past year, against +16.6% for the S&P 500.
Who are Interpace Biosciences's competitors?
Companies most similar to Interpace Biosciences by business, industry and size include TLSI, PROF, PRPO, DCTH, BDMD.
See a number that looks wrong?